Did you know?

  • Allergy is among the world’s most common chronic diseases
  • 20% of the world population suffers from an allergy
  • Current test methods (particularly for food allergy) are not sufficient for an unambiguous allergy diagnosis

Allergios’® direct allergy test enables patients to be better diagnosed and effectively treated

The Challenge

Allergy is among the most common chronic diseases worldwide. Up to 20% of patients with allergies live with a severe debilitating form of their condition, and struggle daily with the fear of a possible asthma attack, anaphylactic shock, or even death from an allergic reaction (EAACI, 2016).

Current tests to diagnose allergy such as the skin prick test and the IgE blood tests, indicate sensitization to allergens, but not necessarily an allergic clinical response. These tests are in the majority of cases not indicative of an actual allergy.

Our Solution

Researchers from the University of Bremen, supported by colleagues at the Medical University of Vienna, have developed a method and system that can directly diagnose allergies by visualizing the allergic response:

the ability of immunological factors in patient blood to induce degranulation of basophils in the presence of allergen

Allergios® offers an effective and scalable In – vitro allergy diagnostic, which works by visually analyzing how a few drops of blood serum enable allergen-specific degranulation of basophil cells. Armed with a disposable microfluidic chip, an optical reader (GranulEye®) and AI based analysis software, allergy tests can be run safely and easily, enabling clinicians to provide timely effective treatment options based on a clear and unambiguous diagnosis by the Allergios® allergy test.

Allergios will initially focus on Food Allergies (replacing the Food Challenge test and the skin prick test) and then gradually expand to Inhalent and other IgE-mediated allergies.

Allergios®– We see allergy.

We see allergy

Our Core Team

Prof. Michael Vellekoop



Dr. Sander van den Driesche



Folkert Roossien

Chief Development Officer


Ernst Elhorst

Chief Executive Officer


Advisory Board

Prof. Dr. Heimo Breiteneder

World-renowned expert on the molecular biology of allergens


Dr. Christine Hafner

Clinical allergist and dermatologist with a focus on molecular allergy diagnostics


Dr. Claas Falldorf

BIAS Germany


Gina Melchner


Venture Partner

Company update

Allergios® has successfully completed the Biological Validation of the Allergios® allergy test in a clinical setting (reaching TRL 5), immensely de-risking the innovation.

Having completed the Biological Validation, Allergios® will focus on raising new capital, aiming for Series-A funding of €2.5m (of which 50% is secured).

Proceeds of this new financing round will be used to secure key personnel and to optimize our test, making it ready for clinical trials under IVDR and FDA guidelines.

We have secured our basic innovation by filing for US and EUR patents, we are currently expanding IP coverage (with flanking IP’s). Both patents have been issued the remarks by the patent offices: “IP to be granted.”

Contact us

"*" indicates required fields

© 2024 Allergios